-
Temafloxacin–Clarithromycin–Ethambutol in MAC
2026-09-28
This 1993 study examined temafloxacin, clarithromycin, and ethambutol against Mycobacterium avium complex using extracellular MIC/FIC testing and macrophage-based intracellular killing assays. Its main contribution was to show that combination effects were strain- and compartment-dependent, with the three-drug combination producing the strongest intracellular bactericidal activity.
-
Carrier-Platin Triggers a Rapid ROS Storm in Cancer Cells
2026-09-28
Liu et al. describe carrier-platin, a polymer-confined platinum nanotherapeutic that rapidly elevates intracellular reactive oxygen species and kills cancer cells through a mode reported to differ from apoptosis and ferroptosis. The findings suggest a distinct direction for platinum-based chemotherapy, although the available evidence is preclinical and the supplied study summary does not provide the detailed protocols needed to reproduce treatment conditions.
-
Carvedilol and the Regenerative Cost of β-Blockade
2026-09-27
Carvedilol’s effects extend beyond cardiovascular signaling. New transplant findings make β-adrenergic receptor research a model for testing how receptor blockade, assay context, and treatment timing shape hematopoietic regeneration.
-
Vidarabine Monohydrate: From Mechanism to Model Design
2026-09-26
A translational framework for using Vidarabine monohydrate to study viral DNA synthesis: connect mechanistic hypotheses to assay controls, compound handling, and evidence appropriate to each research stage.
-
Chloramphenicol for Reliable Plasmid Selection
2026-09-25
A scenario-driven guide to using Chloramphenicol (SKU A2512) in bacterial plasmid selection and resistance studies, with practical concentration, handling, and interpretation guidance. It also explains why a bacterial selection antibiotic should not be treated as a routine cell-viability assay reagent.
-
Bradykinin BA5201: Practical Assay Workflow
2026-09-25
Bradykinin BA5201 provides a defined peptide stimulus for vascular reactivity, permeability, smooth muscle, pain, and inflammation studies. Use it in controlled research workflows, not for diagnostic, therapeutic, or other medical purposes; the product information does not provide an assay dose or a validated preparation recipe.
-
Canine Staphylococci: Mupirocin and Novobiocin
2026-09-24
This study compared in vitro mupirocin and novobiocin susceptibility in meticillin-susceptible and meticillin-resistant staphylococci isolated from healthy dogs and dogs with superficial pyoderma. Mupirocin susceptibility was broadly retained across groups, while novobiocin susceptibility was lower in resistant isolates from healthy dogs; the small isolate sets mean these findings should guide further testing rather than serve as population-wide estimates.
-
WM-8014: Timing KAT6A Inhibition in Cancer Models
2026-09-24
WM-8014 is a potent KAT6A inhibitor for probing how acetyltransferase activity supports cancer-cell states. This guide focuses on a practical question often missed in inhibitor workflows: when to perturb KAT6A, and how to distinguish senescence, cell-cycle arrest, and nonspecific toxicity.
-
Salinomycin for HCC Cell Assay Design
2026-09-23
Practical guidance for using Salinomycin (SKU A3785) in hepatocellular carcinoma research, from stock preparation to interpreting viability and apoptosis readouts. The article distinguishes product specifications from workflow recommendations and highlights the limits of current evidence.
-
Polyethylenimine Linear: PEI MW 40,000 Workflows
2026-09-23
Build reproducible DNA-delivery workflows for transient gene expression, reporter assays, and recombinant protein production with serum-compatible Polyethylenimine Linear. This guide translates a KEAP1-NRF2 cardiotoxicity study into practical transfection controls, optimization steps, and troubleshooting decisions.
-
TBXA2R–ERM Signaling Drives TNBC Metastasis
2026-09-22
The reference study identifies TBXA2R as a GPCR that activates ERM proteins through Gαq/11, Gα12/13, Rho GTPases, and the kinases SLK and LOK. This pathway links receptor signaling to triple-negative breast cancer motility, invasion, and metastatic colonization, while providing a framework for testing cytoskeletal control in disease-relevant models.
-
Kanamycin Sulfate: Mechanism and Research Use
2026-09-22
Kanamycin Sulfate is a water-soluble antibiotic and aminoglycoside research reagent that inhibits bacterial protein synthesis through 30S ribosome binding. Product specifications for SKU A2516 define its composition, solubility, purity, and storage requirements, while peer-reviewed aminoglycoside literature provides mechanistic and comparative context.
-
Temafloxacin: Applied Assay Workflows
2026-09-21
Temafloxacin supports reproducible antibacterial workflows spanning broth MIC testing, intracellular mycobacterial assays, and respiratory infection models. This guide connects assay concentration design with pharmacokinetic evidence, solvent handling, controls, and troubleshooting so researchers can distinguish true antibacterial effects from experimental artifacts.
-
Ultrafiltration for Circular RNA Purification
2026-09-21
Guillen-Cuevas and colleagues evaluate ultrafiltration as a scalable approach for separating protein-encoding circular RNA from linear and nicked RNA produced during in vitro transcription and self-splicing. The study combines membrane sieving measurements with critical-flux analysis and reports better purity–yield performance than size-exclusion HPLC, while also identifying practical considerations for future process development.
-
Kanamycin Sulfate: Mechanism and Research Use
2026-09-20
Kanamycin Sulfate is a water-soluble antibiotic and aminoglycoside research reagent that inhibits bacterial protein synthesis through 30S ribosome binding. Product specifications support controlled microbiology selection, antibiotic resistance research, and mechanism-focused assays when solvent, storage, and resistance boundaries are documented.